Abstract TH256: Metformin Exposure During Polyendocrine Metabolic Ovarian Syndrome (PMOS) Pregnancy: Offspring Cardiometabolic Outcomes
Hypertension · 2026-10 · 83 (Suppl_1)
DOI: 10.1161/hyp.83.suppl_1.th256 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hypertension, 2026-10. Verfasst von Olabisi Ogunlewe und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Polyendocrine metabolic ovarian syndrome (PMOS), previously called polycystic ovary syndrome, is the most common endocrinopathy in young women that is associated with obesity and hyperandrogenemia. Metformin is a standard therapy for women with PMOS, is considered safe during pregnancy and rapidly crosses the placenta. However, long-term sex-specific programming effects of metformin on metabolic and vascular function in PMOS offspring are not clear. We hypothesize that maternal metformin therapy during pregnancy in PMOS confers long-term vascular and metabolic protection in offspring (both sexes) as adults.
Methods
Female Sprague Dawley (SD) rats (4 weeks-old) were implanted with either 5α-dihydrotestosterone (DHT, 7.5mg/90d, s.c.; hyperandrogenemic females (HAF); PMOS model) or a placebo pellet (CON). Females were fed either chow diet (CD) or metformin diet (MET; 300mg/kg/day in CD) starting at 7 weeks-old, creating 4 maternal groups: CON-CD, CON-MET, HAF-CD, and HAF-MET. Females were paired with SD males, allowed to get pregnant, deliver and lactate their offspring. Offspring body weight and composition as adults (4 months) were recorded and offspring (both sexes) were euthanized and aortas were collected (n=6-8). Endothelial function was assessed by measuring the response of isolated phenylephrine (PhE, 3x10-7M) pre-contracted aortic rings to acetylcholine (Ach, 10-9-3x10-5M). The response to L-NAME (10-4 M) was also determined in separate rings (DMT wire myography). Data were analyzed with 2-way ANOVA and Tukey post-hoc.
Results
In adult offspring of both sexes, body weight, and fat and lean masses of HAF-MET offspring were significantly lower (p
Zitieren
APA
Ogunlewe, O., Agbo, J., Willis, A., & Elsayed, N. M. S. (2026). Abstract TH256: Metformin Exposure During Polyendocrine Metabolic Ovarian Syndrome (PMOS) Pregnancy: Offspring Cardiometabolic Outcomes. Hypertension, 83(Suppl_1). https://doi.org/10.1161/hyp.83.suppl_1.th256
Vancouver
Ogunlewe O, Agbo J, Willis A, Elsayed NMS. Abstract TH256: Metformin Exposure During Polyendocrine Metabolic Ovarian Syndrome (PMOS) Pregnancy: Offspring Cardiometabolic Outcomes. Hypertension. 2026;83(Suppl_1). doi:10.1161/hyp.83.suppl_1.th256
BibTeX
@article{Ogunlewe2026,
author = {Ogunlewe, Olabisi and Agbo, John and Willis, Alex and Elsayed, Noha M Shawky},
title = {Abstract TH256: Metformin Exposure During Polyendocrine Metabolic Ovarian Syndrome (PMOS) Pregnancy: Offspring Cardiometabolic Outcomes},
journal = {Hypertension},
year = {2026},
volume = {83},
number = {Suppl_1},
doi = {10.1161/hyp.83.suppl_1.th256}
}
EUVIMED